QPPV.COM KNOWLEDGE ASSESSMENT

Article 31 Pharmacovigilance Referral: Legal Basis, Procedure and Regulatory Consequences in the EU

Test your understanding of the concepts covered by Article 31 Pharmacovigilance Referral: Legal Basis, Procedure and Regulatory Consequences in the EU.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which combination best characterises a pharmacovigilance Article 31 referral?

A routine signal-management activity conducted exclusively by an MAH A Union-level statutory procedure arising from evaluation of pharmacovigilance data where the interests of the Union are involved A Commission procedure used only to withdraw centrally authorised medicines A national variation procedure for updating product information

Question 2 of 10 When may a regulatory outcome involving risk minimisation be considered proportionate?

When the risk is ignored because it is uncommon When the risk can be controlled sufficiently through measures such as warnings, monitoring, contraindications or educational tools while benefits remain acceptable Only when causality has been proven with absolute certainty Only when the product is suspended first

Question 3 of 10 What should a QPPV primarily demonstrate after an Article 31 referral has concluded?

That the QPPV personally made the Commission decision That the pharmacovigilance system incorporated the outcome, implementation was governed and ongoing monitoring remains appropriate That routine signal management was discontinued That all scientific uncertainty was eliminated

Question 4 of 10 What is the most defensible way to handle procedural deadlines for re-examination?

Apply a standard deadline from memory to every referral Assume that the date of the PRAC recommendation is the only relevant date Check the current applicable legislation and referral-specific EMA documents for the notification and detailed-ground deadlines Allow the MAH to set its own deadline

Question 5 of 10 Which statement about causality is most consistent with the article?

Every temporal association proves causality Regulatory action always requires absolute proof of causation Causality is assessed as part of the evidence, but protective regulatory measures may be justified when a sufficient level of concern exists despite residual uncertainty Causality is irrelevant to benefit-risk evaluation

Question 6 of 10 A safety issue is first detected in one nationally authorised product, but the formal referral later includes several products from different MAHs containing the same active substance. What should determine the products formally within scope?

Only the product in which the first case was reported The pharmacological similarity of products, without consulting regulatory documents The formal referral notice and subsequent procedural documents The MAH's preferred scope in its scientific response

Question 7 of 10 For nationally authorised medicinal products, what is CMDh's role after the PRAC recommendation?

To repeat the entire pharmacovigilance assessment independently from the beginning To consider the PRAC recommendation within the regulatory framework for nationally authorised products To replace the European Commission in every referral To decide whether the safety signal is medically valid before PRAC review

Question 8 of 10 What is PRAC primarily responsible for in a pharmacovigilance Article 31 referral?

Issuing the final Commission decision Coordinating national administrative implementation Conducting the pharmacovigilance assessment, evaluating benefit-risk implications and adopting the applicable recommendation Approving all marketing authorisation variations independently of other committees

Question 9 of 10 Which statement best reflects the relationship between an Article 31 referral and subsequent pharmacovigilance?

The referral permanently replaces routine signal management Once the Commission decision is published, no further monitoring is needed The outcome becomes part of the product lifecycle and should inform continued surveillance, risk-management activities and effectiveness monitoring Post-referral monitoring is required only if the product is withdrawn

Question 10 of 10 What is the principal regulatory function of the referral notification?

To establish the final binding regulatory measure To define the products, safety issue, formal questions and Union-level procedural context To replace the PRAC scientific assessment To document only the date on which the first adverse event occurred

Article 31 Pharmacovigilance Referral: Legal Basis, Procedure and Regulatory Consequences in the EU

Cookie Settings